Cyclosporin A reduces matrix metalloproteinases and collagen expression in dermal fibroblasts from regenerative FOXN1 deficient (nude) mice

Fibrogenesis & Tissue Repair

Heather Kirk-Ballard²  Barbara Gawronska-Kozak¹ 

[1] Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, ul. Tuwima 10, Olsztyn, 10-748, Poland;Regenerative Biology Laboratory, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Rd, Baton Rouge, LA 70808, USA

关键词: Scarless healing;    Nude mice;    Matrix metalloproteinases;    Dermal fibroblasts;    Cyclosporin A;   

Others  :  803257
DOI  :  10.1186/1755-1536-6-7

 received in 2012-11-20, accepted in 2013-02-11,  发布年份 2013

【 摘 要 】

Background

Cyclosporin A (CsA), an immunosuppressive agent modifies the wound healing process through an influence on extracellular matrix metabolism. We have compared the effects of CsA on dermal fibroblasts from nude (FOXN1 deficient) mice, a genetic model of skin scarless healing, and from control (C57BL/6 J (B6) mice to evaluate metabolic pathways that appear to have important roles in the process of scarless healing/regeneration.

Results

High levels of matrix metalloproteinases (MMPs) and collagen III expression in dermal fibroblasts from nude (regenerative) mice were down-regulated by CsA treatment to the levels observed in dermal fibroblasts from B6 (non-regenerative) mice. In contrast, dermal fibroblasts from control mice respond to CsA treatment with a minor reduction of Mmps mRNA and 2.5-fold increase expression of collagen I mRNA. An in vitro migratory assay revealed that CsA treatment profoundly delayed the migratory behavior of dermal fibroblasts from both nude and control mice.

Conclusion

The data suggest that by alternation of the accumulation of extracellular matrix components CsA treatment stimulates the transition from a scarless to a scar healing.

【 授权许可】

   
2013 Gawronska-Kozak and Kirk-Ballard; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Kataoka M, Kido J, Shinohara Y, Nagata T: Drug-induced gingival overgrowth–a review. Biol Pharm Bull 2005, 28(10):1817-1821.
• [2]Szpaderska AM, Zuckerman JD, DiPietro LA: Differential injury responses in oral mucosal and cutaneous wounds. J Dent Res 2003, 82(8):621-626.
• [3]McKeown ST, Barnes JJ, Hyland PL, Lundy FT, Fray MJ, Irwin CR: Matrix metalloproteinase-3 differences in oral and skin fibroblasts. J Dent Res 2007, 86(5):457-462.
• [4]Ravanti L, Hakkinen L, Larjava H, Saarialho-Kere U, Foschi M, Han J, Kahari VM: Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. J Biol Chem 1999, 274(52):37292-37300.
• [5]Dannewitz B, Edrich C, Tomakidi P, Kohl A, Gabbert O, Eickholz P, Steinberg T: Elevated gene expression of MMP-1, MMP-10, and TIMP-1 reveal changes of molecules involved in turn-over of extracellular matrix in cyclosporine-induced gingival overgrowth. Cell Tissue Res 2006, 325(3):513-522.
• [6]Dannewitz B, Edrich C, Tomakidi P, Kohl A, Gabbert O, Staehle HJ, Steinberg T: Elevated levels of gene expression for collagen and decorin in human gingival overgrowth. J Clin Periodontol 2006, 33(7):510-516.
• [7]Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Yamashita K, Ninomiya M, Morisaki I, Ohsaki Y, Kido JI, Nagata T: Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol 2000, 182(3):351-358.
• [8]Chan MW, Arora PD, McCulloch CA: Cyclosporin inhibition of collagen remodeling is mediated by gelsolin. Am J Physiol Cell Physiol 2007, 293(3):C1049-1058.
• [9]Bolzani G, Della Coletta R, Martelli Junior H, Graner E: Cyclosporin A inhibits production and activity of matrix metalloproteinases by gingival fibroblasts. J Periodontal Res 2000, 35(1):51-58.
• [10]Sukkar TZ, Thomason JM, Cawston TE, Lakey R, Jones D, Catterall J, Seymour RA: Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines. J Periodontal Res 2007, 42(6):580-588.
• [11]Hyland PL, Traynor PS, Myrillas TT, Marley JJ, Linden GJ, Winter P, Leadbetter N, Cawston TE, Irwin CR: The effects of cyclosporin on the collagenolytic activity of gingival fibroblasts. J Periodontol 2003, 74(4):437-445.
• [12]Fahmy GH, Sicard RE: A role for effectors of cellular immunity in epimorphic regeneration of amphibian limbs. In Vivo 2002, 16(3):179-184.
• [13]Gawronska-Kozak B: Regeneration in the ears of immunodeficient mice: identification and lineage analysis of mesenchymal stem cells. Tissue Eng 2004, 10(7–8):1251-1265.
• [14]Gawronska-Kozak B, Bogacki M, Rim JS, Monroe WT, Manuel JA: Scarless skin repair in immunodeficient mice. Wound Repair Regen 2006, 14:265-276.
• [15]Manuel JA, Gawronska-Kozak B: Matrix metalloproteinase 9 (MMP-9) is upregulated during scarless wound healing in athymic nude mice. Matrix Biol 2006, 25:505-514.
• [16]Gawronska-Kozak B: Scarless skin wound healing in FOXN1 deficient (nude) mice is associated with distinctive matrix metalloproteinase expression. Matrix Biol 2011, 30(4):290-300.
• [17]Watanabe S, Mochizuki A, Wagatsuma K, Kobayashi M, Kawa Y, Takahashi H: Hair growth on nude mice due to cyclosporin A. J Dermatol 1991, 18(12):714-719.
• [18]Takahashi T, Kamimura A: Cyclosporin a promotes hair epithelial cell proliferation and modulates protein kinase C expression and translocation in hair epithelial cells. J Invest Dermatol 2001, 117(3):605-611.
• [19]Moriya C, Jinnin M, Yamane K, Maruo K, Muchemwa FC, Igata T, Makino T, Fukushima S, Ihn H: Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3 and PKC-delta in normal human dermal fibroblasts. J Invest Dermatol 2011, 131(3):655-661.
• [20]Kyriakides TR, Wulsin D, Skokos EA, Fleckman P, Pirrone A, Shipley JM, Senior RM, Bornstein P: Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol 2009, 28(2):65-73.
• [21]Naviaux RK, Le TP, Bedelbaeva K, Leferovich J, Gourevitch D, Sachadyn P, Zhang XM, Clark L, Heber-Katz E: Retained features of embryonic metabolism in the adult MRL mouse. Mol Genet Metab 2009, 96(3):133-144.
• [22]Cotrim P, de Andrade CR, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD: Expression of matrix metalloproteinases in cyclosporin-treated gingival fibroblasts is regulated by transforming growth factor (TGF)-beta1 autocrine stimulation. J Periodontol 2002, 73(11):1313-1322.
• [23]Dannewitz B, Tomakidi P, Syagailo Y, Kohl A, Staehle HJ, Eickholz P, Komposch G, Steinberg T: Elevation of collagen type I in fibroblast-keratinocyte cocultures emphasizes the decisive role of fibroblasts in the manifestation of the phenotype of cyclosporin A-induced gingival overgrowth. J Periodontal Res 2009, 44(1):62-72.
• [24]Abe M, Yokoyama Y, Syuto T, Ishibuchi H, Ishikawa O: Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts. Cell Tissue Res 2008, 333(2):281-288.
• [25]Dang C, Ting K, Soo C, Longaker MT, Lorenz HP: Fetal wound healing current perspectives. Clin Plast Surg 2003, 30(1):13-23.
• [26]Stanway A, Rademaker M, Newman P: Healing of severe ulcerative necrobiosis lipoidica with cyclosporin. Australas J Dermatol 2004, 45(2):119-122.
• [27]Patrone P, Stinco G, La Pia E, Frattasio A, De Francesco V: Surgery and cyclosporine A in the treatment of erosive lichen planus of the feet. Eur J Dermatol 1998, 8(4):243-244.
• [28]Toriseva M, Kahari VM: Proteinases in cutaneous wound healing. Cell Mol Life Sci 2009, 66(2):203-224.
• [29]Ulrich D, Ulrich F, Unglaub F, Piatkowski A, Pallua N: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids. J Plast Reconstr Aesthet Surg 2010, 63(6):1015-1021.
• [30]Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G: Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999, 7(6):442-452.
• [31]Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H: Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002, 45(7):1011-1016.
• [32]Yang C, Zhu P, Yan L, Chen L, Meng R, Lao G: Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats. J Am Podiatr Med Assoc 2009, 99(6):489-496.
• [33]Dang CM, Beanes SR, Lee H, Zhang X, Soo C, Ting K: Scarless fetal wounds are associated with an increased matrix metalloproteinase-to-tissue-derived inhibitor of metalloproteinase ratio. Plast Reconstr Surg 2003, 111(7):2273-2285.
• [34]Leivonen SK, Chantry A, Hakkinen L, Han J, Kahari VM: Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. J Biol Chem 2002, 277(48):46338-46346.
• [35]Gawronska-Kozak B, Manuel JA, Prpic V: Ear mesenchymal stem cells (EMSC) can differentiate into spontaneously contracting muscle cells. J Cell Biochem 2007, 102(1):122-135.